['advanced solid tumors']
['veliparib (abt-888)']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed malignant solid tumor, and any of the
             following: * Subjects with recurrent high grade serous ovarian cancer who completed or
             discontinued platinum based therapy; * Subjects with BRCA-mutated breast cancer who
             have received prior chemotherapy with anthracycline and/or taxanes; * Subjects with
             deleterious mutations of BRCA with advanced solid tumors who have received available
             standard therapies.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Life expectancy of greater than 12 weeks.

          -  Adequate organ and marrow function· Measurable or non-measurable disease.

        Exclusion Criteria:

          -  Major surgery and/or radiation within (<) 4 weeks prior to study enrollment.

          -  Chemotherapy or hormone therapy within (<) 4 weeks prior to study enrollment except
             for mitomycin C and nitrosoureas, in which case it is 6 weeks.

          -  Any investigational agents within (<) 4 weeks prior to study enrollment.

          -  Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study
             enrollment.

          -  Toxicities (with the exception of alopecia) from prior major surgery, radiation, or
             systemic chemotherapy have not recovered to less than grade 2.
      